OARS funding Cancer

This Funding Opportunity Announcement (FOA) will support innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention.

The RAN grant provides a total of $1 million to pancreatic cancer research projects that include a clinical project designed to improve the prevention, detection/diagnosis/ prognosis, treatment, or supportive care for pancreatic cancer. 

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought.

The purpose of this funding opportunity announcement (FOA) is to stimulate mechanistic research on the pathophysiological effects of inhaled nicotine on the respiratory and cardiovascular systems in the context of non-cancer heart and lung diseases. 

This Funding Opportunity Announcement (FOA) solicits research projects focused on the process of effective communication of research findings about breast cancer and the environment. A central objective of this new initiative is to ensure effective translation of findings that result in risk messaging that is understood by targeted audiences.  The ultimate goal is to provide the scientific evidence for developing communication-based prevention efforts to reduce the risk for breast cancer from environmental factors.  

The goal of this Funding Opportunity Announcement (FOA) is to facilitate the planning, designing and initial research focus of Regional Centers of Research Excellence (RCRE) for non-communicable disease, including cancer, in low and middle-income countries (LMICs). Activities in this FOA will be implemented through collaborative partnerships between investigators from institutions in high-income countries (HICs) or upper- middle-income countries (UMICs) and investigators, research administrators, and other stakeholders from LMICs. 

Alliance for Cancer Gene Therapy, Inc. (ACGT) funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. To this end, ACGT offers awards in Clinical Translation of Cell and Gene Therapy for Cancer, to qualified scientists at the assistant professor level and above. This award is specifically for those conducting Cell and Gene Therapy Research for sarcoma and is entitled, The Wendy Walk/ACGT Sarcoma Research Grant.

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research provides funding in a range of areas, including funding for innovative pilot studies, scholar grants to up-and-coming investigators, early detection screening for ovarian cancer, and research symposia on ovarian cancer.

The goal of this Funding Opportunity Announcement (FOA) is to facilitate the planning, designing and initial research focus of Regional Centers of Research Excellence (RCRE) for non-communicable disease, including cancer, in low and middle-income countries (LMICs). 

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Childhood Cancer Survivor Study (CCSS) as a resource enabling broad studies on the long-term effects of cancer and its associated therapies on survivors of pediatric cancers. 

The purpose of this Notice is to inform new NIH applicants, their mentors, and grant administrators at their institution about two upcoming webinars the NIH Center for Scientific Review (CSR) is hosting in November 2015.  These webinars are designed to give participants useful insights into our application submission and peer review processes.  CSR is the portal for NIH grant applications and their review for scientific and technical merit.

Through the program, the center will award three grants of up to $60,000 each to promising laboratory and clinical scientists interested in pursuing a career as an independent investigator in ovarian cancer research. Funds are for direct costs only; institutional overhead and indirect costs will not be included in the award.

The University of Chicago is offering talented individuals from traditionally underrepresented populations an expenses-paid opportunity to explore graduate education at the University of Chicago. Join us for a weekend of graduate admissions workshops, presentations by world-renowned faculty and their graduate students, and informal socials. Receive advice on submitting a competitive application to graduate programs and learn how to develop your own career as a scientist, academic, or professional.

The National Institutes of Health (NIH) seeks input on the restructuring of the NIH grant application instructions. We invite comments from any interested parties. We encourage feedback from PD/PIs, Administrative Offices, Offices of Sponsored Programs, Systems Administrators, and any other parties that rely on our application submission information.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources.  This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field.  In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement/Funding Opportunity. An additional funding level, Funding Level 3, is available under a different Program Announcement (W81XWH-15-BCRP-BREAKTHROUGH2_FL3). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: * Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. * Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable. Partnering PI Option: The Breakthrough Award encourages applications that includ

The National Cancer Institute (NCI) will fund a new Cancer Systems Biology Consortium (CSBC) that includes U54 CSBC Research Centers, a Coordinating Center (to be supported under companion U24 RFA-CA-15-015) and other related research projects supported through the U01 mechanism. The CSBC initiative aims to address challenges of complexity in basic and translational cancer research through the use of experimental biology combined with in silico modeling, multi-dimensional data analysis, and systems engineering.

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for 7-year grants. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.